Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

among other eye conditions (marketed as Eylea), and again in August 2012 to treat metastatic colorectal cancer (marketed as Zaltrap). Both were formed in partnership with Sanofi (SNY), which was ...

Valued at a market cap of $76.6 billion, the company’s portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst, and Zaltrap. The biotech ...

Valued at $73.8 billion by market cap, the company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. Companies worth $ ...

The company’s products include EYLEA injection to treat wet age-related ... inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic ...

Here's the rundown. Regeneron's issues in the past year are almost entirely related to Eylea, a medicine for wet age-related macular degeneration, which it co-markets with Bayer. The Eylea ...

Total revenues increased 10% year over year to $3.79 billion, fueled by increased collaboration revenues from Sanofi for Dupixent, higher Eylea HD and Libtayo sales. Revenues marginally beat the ...

The other three — Tofidence™ and Tyenne® for Actemra® (tocilizumab) and Pavblu™ for Eylea® (aflibercept) — were the first commercially available biosimilars for their respective ...

"We are extremely pleased with this new step in the development of our biosimilar candidate to Eylea ®, as better access will benefit patients and their caregivers," said Joseph McClellan ...